Carol I. Lord
Harvard University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Carol I. Lord.
Journal of Virology | 2005
Sampa Santra; Michael S. Seaman; Ling Xu; Dan H. Barouch; Carol I. Lord; Michelle A. Lifton; Darci A. Gorgone; Kristin Beaudry; Krisha Svehla; Brent Welcher; Bimal K. Chakrabarti; Yue Huang; Zhi-Yong Yang; John R. Mascola; Gary J. Nabel; Norman L. Letvin
ABSTRACT The magnitude and durability of immune responses induced by replication-defective adenovirus serotype 5 (ADV5) vector-based vaccines were evaluated in the simian-human immunodeficiency virus/rhesus monkey model. A single inoculation of recombinant ADV5 vector constructs induced cellular and humoral immunity, but the rapid generation of neutralizing anti-Ad5 antibodies limited the immunity induced by repeated vector administration. The magnitude and durability of the immune responses elicited by these vaccines were greater when they were delivered as boosting immunogens in plasmid DNA-primed monkeys than when they were used as single-modality immunogens. Therefore, administration of ADV5-based vectors in DNA-primed subjects may be a preferred use of this vaccine modality for generating long-term immune protection.
Journal of Virology | 2001
Dan H. Barouch; Abie Craiu; Sampa Santra; Michael A. Egan; Jörn E. Schmitz; Marcelo J. Kuroda; Tong-Ming Fu; Jae-Hwan Nam; Linda S. Wyatt; Michelle A. Lifton; Georgia R. Krivulka; Christine E. Nickerson; Carol I. Lord; Bernard Moss; Mark G. Lewis; Vanessa M. Hirsch; John W. Shiver; Norman L. Letvin
ABSTRACT Increasing evidence suggests that the generation of cytotoxic T-lymphocyte (CTL) responses specific for a diversity of viral epitopes will be needed for an effective human immunodeficiency virus type 1 (HIV-1) vaccine. Here, we determine the frequencies of CTL responses specific for the simian immunodeficiency virus Gag p11C and HIV-1 Env p41A epitopes in simian-human immunodeficiency virus (SHIV)-infected and vaccinated rhesus monkeys. The p11C-specific CTL response was high frequency and dominant and the p41A-specific CTL response was low frequency and subdominant in both SHIV-infected monkeys and in monkeys vaccinated with recombinant modified vaccinia virus Ankara vectors expressing these viral antigens. Interestingly, we found that plasmid DNA vaccination led to high-frequency CTL responses specific for both of these epitopes. These data demonstrate that plasmid DNA may be useful in eliciting a broad CTL response against multiple epitopes.
Journal of Virology | 2005
Philip R. Johnson; Bruce C. Schnepp; Mary J. Connell; Daniela Rohne; Suzanne Robinson; Georgia R. Krivulka; Carol I. Lord; Rebekah L. Zinn; David C. Montefiori; Norman L. Letvin; K. Reed Clark
ABSTRACT Gene transfer vectors based on recombinant adeno-associated virus (rAAV) are simple, versatile, and safe. While the conventional applications for rAAV vectors have focused on delivery of therapeutic genes, we have developed the system for delivery of vaccine antigens. In particular, we are interested in generating rAAV vectors for use as a prophylactic human immunodeficiency virus type 1 (HIV-1) vaccine. To that end, we constructed vaccine vectors that expressed genes from the simian immunodeficiency virus (SIV) for evaluation in the monkey SIV model. After a single intramuscular dose, rAAV/SIV vaccines elicited SIV-specific T cells and antibodies in macaques. Furthermore, immunized animals were able to significantly restrict replication of a live, virulent SIV challenge. These data suggest that rAAV vaccine vectors induced biologically relevant immune responses, and thus, warrant continued development as a viable HIV-1 vaccine candidate.
Nature Immunology | 2005
Dan H. Barouch; Jennifer Powers; Diana M. Truitt; Michael G. Kishko; Janelle C. Arthur; Fred W. Peyerl; Marcelo J. Kuroda; Darci A. Gorgone; Michelle A. Lifton; Carol I. Lord; Vanessa M. Hirsch; David C. Montefiori; Angela Carville; Keith G. Mansfield; Kevin J. Kunstman; Steven M. Wolinsky; Norman L. Letvin
Viral escape from cytotoxic T lymphocytes (CTLs) can undermine immune control of human immunodeficiency virus 1. It is therefore important to assess the stability of viral mutations in CTL epitopes after transmission to naive hosts. Here we demonstrate the persistence of mutations in a dominant CTL epitope after transmission of simian immunodeficiency virus variants to major histocompatibility complex–matched rhesus monkeys. Transient reversions to wild-type sequences occurred and elicited CTLs specific for the wild-type epitope, resulting in immunological pressure that rapidly reselected the mutant viruses. These data suggest that mutations in dominant human immunodeficiency virus 1 CTL epitopes may accumulate in human populations with limited major histocompatibility complex heterogeneity by a mechanism involving dynamic CTL control of transiently reverted wild-type virus.
Journal of Immunology | 2002
Sampa Santra; Jörn E. Schmitz; Marcelo J. Kuroda; Michelle A. Lifton; Christine E. Nickerson; Carol I. Lord; Ranajit Pal; Genoveffa Franchini; Norman L. Letvin
Since virus-specific CTL play a central role in containing HIV replication, a candidate AIDS vaccine should generate virus-specific CTL responses. In this study, the ability of a recombinant canarypox virus expressing SIV Gag-Pol-Env (ALVAC/SIV gag-pol-env) was assessed for its ability to elicit both dominant and subdominant epitope-specific CTL responses in rhesus monkeys. Following a series of five immunizations, memory CTL responses specific for a dominant Gag epitope could be demonstrated in the peripheral blood of vaccinated monkeys. Memory CTL responses to a subdominant Pol epitope were undetectable in these animals. Following challenge with SIVmac251, the experimentally vaccinated animals developed high frequency CTL responses specific for the dominant Gag epitope that emerged in temporal association with the early containment of viral replication. Interestingly, the experimentally vaccinated, but not the control vaccinated animals, developed CTL responses to the subdominant Pol epitope that were detectable only after containment of early viremia. Thus, recombinant canarypox vaccination elicited low frequency, but durable memory CTL populations. The temporal association of the emergence of the dominant epitope-specific response with early viral containment following challenge suggests that this immune response played a role in the accelerated clearing of early viremia in these animals. The later emerging CTL response specific for the subdominant epitope may contribute to the control of viral replication in the setting of chronic infection.
Journal of Virology | 2001
Suzanne Robinson; William A. Charini; Michael H. Newberg; Marcelo J. Kuroda; Carol I. Lord; Norman L. Letvin
ABSTRACT The ability to monitor vaccine-elicited CD8+ cytotoxic T-lymphocyte (CTL) responses in simian immunodeficiency virus (SIV)- and simian-human immunodeficiency virus (SHIV)-infected rhesus monkeys has been limited by our knowledge of viral epitopes predictably presented to those lymphocytes by common rhesus monkey MHC class I alleles. We now define an SIV and SHIV Nef CTL epitope (YTSGPGIRY) that is presented to CD8+ T lymphocytes by the common rhesus monkey MHC class I molecule Mamu-A*02. All seven infectedMamu-A*02 + monkeys evaluated demonstrated this response, and peptide-stimulated interferon gamma Elispot assays indicated that the response represents a large proportion of the entire CD8+ T-lymphocyte SIV- or SHIV-specific immune response of these animals. Knowledge of this epitope and MHC class I allele substantially increases the number of available rhesus monkeys that can be used for testing prototype HIV vaccines in this important animal model.
Journal of Virology | 2002
Sampa Santra; Dan H. Barouch; Marcelo J. Kuroda; Jörn E. Schmitz; Georgia R. Krivulka; Kristin Beaudry; Carol I. Lord; Michelle A. Lifton; Linda S. Wyatt; Bernard Moss; Vanessa M. Hirsch; Norman L. Letvin
ABSTRACT Although recent evidence has confirmed the importance of cytotoxic T-lymphocyte (CTL) responses in controlling human immunodeficiency virus type 1 and simian immunodeficiency virus replication, the relevance of the epitopic breadth of those CTL responses remains unexplored. In the present study, we sought to determine whether vaccination can expand CTL populations which recognize a repertoire of viral epitopes that is greater than is typically generated in the course of a viral infection. We demonstrate that potent secondary CTL responses to subdominant epitopes are rapidly generated following a pathogenic simian-human immunodeficiency virus challenge of rhesus monkeys vaccinated with plasmid DNA or recombinant modified vaccinia virus Ankara vaccines. These data indicate that prior vaccination can increase the breadth of the CTL response that evolves after an AIDS virus infection.
Proceedings of the National Academy of Sciences of the United States of America | 1997
Norman L. Letvin; David C. Montefiori; Yasuhiro Yasutomi; Helen C. Perry; Mary-Ellen Davies; Christine Lekutis; Marianne Alroy; Daniel C. Freed; Carol I. Lord; Laurence K. Handt; Margaret A. Liu; John W. Shiver
Journal of Immunology | 1999
Marcelo J. Kuroda; Jörn E. Schmitz; William A. Charini; Christine E. Nickerson; Michelle A. Lifton; Carol I. Lord; Meryl A. Forman; Norman L. Letvin
Nature | 1992
David I. Watkins; Stephen N. McAdam; Xiaomin Liu; Clarice R. Strang; Edgar L. Milford; Cindy G. Levine; Theodore L. Garber; Alex L. Dogon; Carol I. Lord; Steven H. Ghim; Gary M. Troup; Austin L. Hughes; Norman L. Letvin